Published: 21 December 2020
Author(s): Sofía Tejada, Miia Jansson, Candela Solé-Lleonart, Jordi Rello
Issue: May 2021
Section: Original article

Influenza is an infection of variable severity resulting in high accumulated mortality worldwide [1]. Seasonal influenza deaths occur mainly in young children and the elderly, while during influenza pandemics young adult individuals are more affected [2,3]. Influenza vaccination is the primary method for preventing and reducing the risk of severe influenza outcomes, but in many cases the result is suboptimal [4,5]. However, the treatment against influenza infection is nearly limited to neuraminidase inhibitors (NAIs) due to the rapid occurrence of resistance to M2 inhibitors (amantadine and rimantadine) observed during the last influenza pandemic in 2009 [6].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.